Current treatment options for esophageal diseases

Annals of the New York Academy of Sciences

Volumn 1381, Issue 1, 2016, Pages 139-151

  Martínek, Jan ^a   Akiyama, Jun Ichi ^b   Vacková, Zuzana ^a   Furnari, Manuele ^c   Savarino, Edoardo ^d   Weijs, Teus J ^e   Valitova, Elen ^f   van der Horst, Sylvia ^g   Ruurda, Jelle P ^g   Goense, Lucas ^g   Triadafilopoulos, George ^h  

^a INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^b NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^c UNIVERSITY OF GENOA   (Italy)

^d UNIVERSITY OF PADOVA   (Italy)

^e DEPARTMENT OF SURGERY   (Netherlands)

^f MM Shemyakin YuA Ovchinnikov I   (Russian Federation)

^g UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^h STANFORD UNIVERSITY   (United States)

Author keywords

Barrett's esophagus; distal esophageal spasm; esophageal carcinoma; esophagectomy; gastroesophageal reflux disease

Indexed keywords

PROTON PUMP INHIBITOR;

ARTICLE; BARRETT ESOPHAGUS; CANCER ADJUVANT THERAPY; CANCER THERAPY; EARLY CANCER; ENDOSCOPIC SURGERY; ESOPHAGUS CANCER; ESOPHAGUS DISEASE; ESOPHAGUS RESECTION; ESOPHAGUS SPASM; GASTROESOPHAGEAL REFLUX; HUMAN; LAPAROSCOPIC SURGERY; META ANALYSIS (TOPIC); MINIMALLY INVASIVE SURGERY; MORTALITY RATE; MULTICENTER STUDY (TOPIC); NEOADJUVANT THERAPY; PEROPERATIVE COMPLICATION; PREOPERATIVE CARE; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; ROBOT ASSISTED SURGERY; SURGICAL MORTALITY; THORACOLAPAROSCOPIC ESOPHAGECTOMY; ANIMAL; ESOPHAGEAL DISEASES; ESOPHAGEAL NEOPLASMS; ESOPHAGOSCOPY; PROCEDURES; TREATMENT OUTCOME; TRENDS;

ANIMALS; BARRETT ESOPHAGUS; ESOPHAGEAL DISEASES; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; ESOPHAGOSCOPY; GASTROESOPHAGEAL REFLUX; HUMANS; PROTON PUMP INHIBITORS; TREATMENT OUTCOME;

EID: 84978269154     PISSN: 00778923     EISSN: 17496632     Source Type: Journal    
DOI: 10.1111/nyas.13146     Document Type: Article

References (102)

1. El-Serag, H.B., S. Sweet, C.C. Winchester & J. Dent. 2014. Update on the epidemiology of gastrooesophageal reflux disease: a systematic review. Gut 63: 871–880.
2. Kahrilas, P.J., N.J. Shaheen, M.F. Vaezi, et al.; American Gastroenterological Association. 2008. American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. Gastroenterology 135: 1383–1391.
3. Fass, R. & D. Sifrim. 2009. Management of heartburn not responding to proton pump inhibitors. Gut 58: 295–309.
4. Sifrim, D. & F. Zerbib. 2012. Diagnosis and management of patients with reflux symptoms refractory to proton pump inhibitors. Gut 61: 1340–1354.
5. Savarino, V., E. Savarino & P. Dulbecco. 2006. Proton pump inhibitor failure: why does it occur and how can it be managed? Digestion 73: 215–217.
6. Savarino, E., D. Pohl, P. Zentilin, et al. 2009. Functional heartburn has more in common with functional dyspepsia than with non-erosive reflux disease. Gut 58: 1185–1191.
7. Martinez, S.D., I.B. Malagon, H.S. Garewal, et al. 2003. Non-erosive reflux disease (NERD) acid reflux and symptom patterns. Aliment Pharmacol. Ther. 17: 537–545.
8. Zentilin, P., P. Dulbecco, E. Savarino, et al. 2004. Combined multichannel intraluminal impedance and pH-metry: a novel technique to improve detection of gastro-oesophageal reflux literature review. Dig. Liver Dis. 36: 565–569.
9. Savarino, E., E. Marabotto, P. Zentilin, et al. 2011. The added value of impedance-pH monitoring to Rome III criteria in distinguishing functional heartburn from non-erosive reflux disease. Dig. Liver Dis. 43: 542–547.
10. Savarino, E., R. Carbone, E. Marabotto, et al. 2013. Gastro-oesophageal reflux and gastric aspiration in idiopathic pulmonary fibrosis patients. Eur. Respir. J. 42: 1322–1331.
11. Savarino, E., P. Zentilin & V. Savarino. 2013. NERD: an umbrella term including heterogeneous subpopulations. Nat. Rev. Gastroenterol. Hepatol. 10: 371–380.
12. Gunaratnam, N.T., T.P. Jessup, J. Inadomi & D.P. Lascewski. 2006. Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease. Aliment Pharmacol. Ther. 23: 1473–1477.
13. de Bortoli, N., G. Guidi, I. Martinucci, et al. 2016. Voluntary and controlled weight loss can reduce symptoms and proton pump inhibitor use and dosage in patients with gastroesophageal reflux disease: a comparative study. Dis. Esophagus 29: 197–204.
14. Colin-Jones, D.G. 1995. The role and limitations of H2-receptor antagonists in the treatment of gastro-esophageal reflux disease. Aliment Pharmacol. Ther. 9(Suppl. 1): 9–14.
15. Kwiatek, M.A., S. Roman, A. Fareeduddin, et al. 2011. An alginate-antacid formulation (Gaviscon Double Action Liquid) can eliminate or displace the postprandial ‘acid pocket’ in symptomatic GERD patients. Aliment Pharmacol. Ther. 34: 59–66.
16. Giannini, E.G., P. Zentilin, P. Dulbecco, et al. 2006. A comparison between sodium alginate and magaldrate anhydrous in the treatment of patients with gastroesophageal reflux symptoms. Dig. Dis. Sci. 51: 1904–1909.
17. Ansorge, S., D. Reinhold & U. Lendeckel. 2003. Propolis and some of its constituents down-regulate DNA synthesis and inflammatory cytokine production but induce TGF-beta1 production of human immune cells. Z. Naturforsch. C 58: 580–589.
18. Palmieri, B., D. Corbascio, S. Capone & D. Lodi. 2009. Preliminary clinical experience with a new natural compound in the treatment of oesophagitis and gastritis: symptomatic effect. Trends Med. 9: 219–225.
19. Vela, M.F., R. Tutuian, P.O. Katz & D.O. Castell. 2003. Baclofen decreases acid and non-acid post-prandial gastro-oesophageal reflux measured by combined multichannel intraluminal impedance and pH. Aliment Pharmacol. Ther. 17: 243–251.
20. Viazis, N., A. Keyoglou, A.K. Kanellopoulos, et al. 2012. Selective serotonin reuptake inhibitors for the treatment of hypersensitive esophagus: a randomized, double-blind, placebo-controlled study. Am. J. Gastroenterol. 107: 1662–1667.
21. Desjardin, M., G. Luc, D. Collet & F. Zerbib. 2016. 24-Hour pH-impedance monitoring on therapy to select patients with refractory reflux symptoms for antireflux surgery. A single center retrospective study. Neurogastroenterol. Motil. 28: 146–152.
22. Fuchs, K.H., B. Babic, W. Breithaupt, et al. European Association of Endoscopic Surgery (EAES). 2014. EAES recommendations for the management of gastroesophageal reflux disease. Surg. Endosc. 28: 1753–1773.
23. International High Resolution Manometry Working Group. 2015. The Chicago classification of esophageal motility disorders, v3.0. Neurogastroenterol. Motil. 27: 160–174.
24. Richter, J.E. & D.O. Castell. 1984. Diffuse esophageal spasm: reappraisal. Ann. Intern. Med. 100: 242–245.
25. Orlando, R.C. & E.M. Bozymski. 1973. Clinical and manometric effects of nytroglycerin in diffuse esophageal spasm. N. Engl. J. Med. 289: 23–25.
26. Fox, M., R. Sweis, T. Wong, et al. 2007. Sildenafil relieves symptoms and normalizes motility in patients with oesophageal spasm: a report of two cases. Neurogastroenterol. Motil. 19: 798–803.
27. Valdovinos, M.A., M.R. Zavala-Solares & E. Coss-Adame. 2014. Esophageal hypomotility and spastic motor disorders: current diagnosis and treatment. Curr. Gastroenterol. Rep. 16: 421.
28. Clouse, R.E., P.J. Lustman, T.C. Eckert, et al. 1987. Low-dose trazodone for symptomatic patients with esophageal contraction abnormalities. A double-blind, placebo-controlled trial. Gastroenterology 92: 1027–1036.
29. Handa, M., K. Mine, H. Yamamoto, et al. 1999. Antidepressant treatment of patients with diffuse esophageal spasm: a psychosomatic approach. J. Clin. Gastroenterol. 28: 228–232.
30. Martínek, J., M. Siroký, Z. Plottová, et al. 2003. Treatment of patients with achalasia with botulinum toxin: a multicenter prospective cohort study. Dis. Esophagus 16: 204–209.
31. Vanuytzel, T., R. Bisschops, R. Farre, et al. 2013. Botulinum toxin reduces dysphagia in patients with nonachalasia primary esophageal motility disorders. Clin. Gastroenterol. Hepatol. 11: 1115–1121.
32. Khashab, M.A., A.A. Messallam, M. Onimaru, et al. 2015. International multicenter experience with peroral endoscopic myotomy for the treatment of spastic esophageal disorders refractory to medical therapy (with video). Gastrointest. Endosc. 81: 1170–1177.
33. Ouatu-Lascar, R. & G. Triadafilopoulos. 1998. Complete elimination of reflux symptoms does not guarantee normalization of intraesophageal acid reflux in patients with Barrett's esophagus. Am. J. Gastroenterol. 93: 711–716.
34. Singh, S. et al. 2014. Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett oesophagus: a systematic review and meta-analysis. Gut 63: 1229–1237.
35. Beales, I.L.P., A. Hensley & Y. Loke. 2013. Reduced esophageal cancer incidence in statin users, particularly with cyclo-oxygenase inhibition. World J. Gastrointest. Pharm. Ther. 4: 69–79.
36. Shaheen, N.J. et al. 2016. ACG Clinical Guideline: Diagnosis and management of Barrett's Esophagus. Am. J. Gastroenterol. 111: 30–50.
37. Maret-Ouda, J. et al. 2016. Antireflux surgery and risk of esophageal adenocarcinoma: a systematic review and meta-analysis. Ann. Surg. 263: 251–257.
38. Orman, E.S., N. Li & N.J. Shaheen. 2013. Efficacy and durability of radiofrequency ablation for Barrett's esophagus: systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 11: 1245–1255.
39. Akiyama, J., S.N. Marcus & G. Triadafilopoulos. 2012. Effective intra-esophageal acid control is associated with improved radiofrequency ablation outcomes in Barrett's esophagus. Dig. Dis. Sci. 57: 2625–2632.
40. Krishnan, K., J.E. Pandolfino, P.J. Kahrilas, et al. 2012. Increased risk for persistent intestinal metaplasia in patients with Barrett's esophagus and uncontrolled reflux exposure before radiofrequency ablation. Gastroenterology 143: 576–581.
41. International Agency for Research on Cancer. 2016. Estimated cancer incidence, mortality and prevalence worldwide in 2012. Accessed May 24, 2016. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx.
42. Spechler, S.J., P. Sharma, R.F. Souza, et al. 2011. AGA medical position statement on the management of Barrett's esophagus. Gastroenterology 140: 1084–1091.
43. Ono, S., M. Fujishiro, K. Niimi, et al. 2009. Predictors of postoperative stricture after esophageal endoscopic submucosal dissection for superficial squamous cell neoplasms. Endoscopy 41: 661–665.
44. Pimentel-Nunes, P., M. Dinis-Ribeiro, T. Ponchon, et al. 2015. Endoscopic submucosal dissection: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 47: 829–854.
45. Martinek, J., M. Stefanova, J. Maluskova, et al. 2013. Radiofrequency ablation in patients with early esophageal neoplasia: a prospective evaluation of 52 consecutive cases. United Eur. Gastroenterol. J. 1(Suppl. 1): A1–A134.
46. Phoa, K.N., R.E. Pouw, R. Bisschops, et al. 2016. Multimodality endoscopic eradication for neoplastic Barrett oesophagus: results of an European multicentre study (EURO-II). Gut 65: 555–562.
47. Pech, O., A. May, H. Manner, et al. 2014. Long-term efficacy and safety of endoscopic resection for patients with mucosal adenocarcinoma of the esophagus. Gastroenterology 146: 652–660.e1.
48. Ell, C., A. May, L. Grossner, et al. 2000. Endoscopic mucosal resection of early cancer and high grade dysplasia in Barrett's esophagus. Gastroenterology 118: 670–677.
49. Phoa, K.N., R.E. Pouw, F.G. van Vilsteren, et al. 2013. Remission of Barrett's Esophagus with early neoplasia 5 years after radiofrequency ablation with endoscopic resection: a Netherlands cohort study. Gastroenterology 145: 96–104.
50. Manner, H., O. Pech, Y. Heldmann, et al. 2015. The frequency of lymph node metastasis in early-stage adenocarcinoma of the esophagus with incipient submucosal invasion (pT1b sm1) depending on histological risk patterns. Surg. Endosc. 29: 1888–1896.
51. Bollschweiler, E., S.E. Baldus, W. Schröder, et al. 2006. High rate of lymph node metastasis in submucosal esophageal squamous cell carcinomas and adenocarcinomas. Endoscopy 38: 149–156.
52. Vieth, M. & M. Stolte. 2005. Pathology of early upper GI cancers. Best Pract. Res. Clin. Gastroenterol. 19: 857–869.
53. Higuchi, K., S. Tanabe, M. Azuma, et al. 2013. A phase II study of endoscopic submucosal dissection for superficial esophageal neoplasms (KDOG 0901). Gastrointest. Endosc. 78: 704–710.
54. Mariette, C. & G. Piessen. 2012. Oesophageal cancer: how radical should surgery be? Eur. J. Surg. Oncol. 38: 210–213.
55. Omloo, J.M., S.Y. Law, B. Launois, et al. 2009. Short and long-term advantages of transhiatal and transthoracic oesophageal cancer resection. Eur. J. Surg. Oncol. 35: 793–797.
56. Shapiro, J., J.J. van Lanschot, M.C. Hulshof, et al. CROSS study group. 2015. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 16: 1090–1098.
57. Ruurda, J.P., W.A. Draaisma, R. van Hillegersberg, et al. 2005. Robot-assisted endoscopic surgery: a four-year single-center experience. Dig. Surg. 22: 313–320.
58. Shen, Y., N. Feng, L. Tan, et al. 2014. Thoracoscopic esophagectomy in prone versus decubitus position: ergonomic evaluation from a randomized and controlled study. Ann. Thorac. Surg. 98: 1072–1078.
59. Versteijne, E., H.W.M. van Laarhoven, J.E. van Hooft, et al. 2015. Definitive chemoradiation for patients with inoperable and/or unresectable esophageal cancer: loco-regional recurrence pattern. Dis. Esophagus 28: 453–459.
60. Gkika, E., T. Gauler, W. Eberhardt, et al. 2014. Long-term results of definitive radiochemotherapy in locally advanced cancers of the cervical esophagus. Dis. Esophagus 27: 678–684.
61. de Boer, A.G.E.M., J.J.B. van Lanschot, J.W. van Sandick, et al. 2004. Quality of life after transhiatal compared with extended transthoracic resection for adenocarcinoma of the esophagus. J. Clin. Oncol. 22: 4202–4208.
62. van Hillegersberg, R., J. Boone, W.A. Draaisma, et al. 2006. First experience with robot-assisted thoracoscopic esophagolymphadenectomy for esophageal cancer. Surg. Endosc. 20: 1435–1439.
63. Boone, J., M.E. Schipper, W.A. Moojen, et al. 2009. Robot-assisted thoracoscopic esophagectomy for cancer. Br. J. Surg. 96: 878–886.
64. van der Sluis, P.C., J.P. Ruurda, R.J. Verhage, et al. 2015. Oncologic long-term results of robot-assisted minimally invasive thoraco-laparoscopic esophagectomy with two-field lymphadenectomy for esophageal cancer. Ann. Surg. Oncol. 22(Suppl. 3): 1350–1356.
65. Ruurda, J.P., P.C. van der Sluis, S. van der Horst, et al. 2015. Robot-assisted minimally invasive esophagectomy for esophageal cancer: a systematic review. J. Surg. Oncol. 112: 257–265.
66. Kim, D.J., S.Y. Park, S. Lee, et al. 2014. Feasibility of a robot-assisted thoracoscopic lymphadenectomy along the recurrent laryngeal nerves in radical esophagectomy for esophageal squamous carcinoma. Surg. Endosc. 28: 1866–1873.
67. Pennathur, A., M.K. Gibson, B.A. Jobe & J.D. Luketich. 2013. Oesophageal carcinoma. Lancet 381: 400–412.
68. Cunningham, D., W.H. Allum, S.P. Stenning, et al. 2006. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N. Engl. J. Med. 355: 11–20.
69. Sjoquist, K.M., B.H. Burmeister, B.M. Smithers, et al. 2011. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 12: 681–692.
70. Ronellenfitsch, U., M. Schwarzbach, R. Hofheinz, et al. 2013. Preoperative chemo(radio)therapy versus primary surgery for gastroesophageal adenocarcinoma: systematic review with meta-analysis combining individual patient and aggregate data. Eur. J. Cancer 49: 3149–3158.
71. Jang, R., G. Darling & R.K. Wong. 2015. Multimodality approaches for the curative treatment of esophageal cancer. J. Natl. Compr. Canc. Netw. 13: 229–238.
72. van Hagen, P., M.C. Hulshof, J.J. van Lanschot, et al. 2012. Preoperative chemoradiotherapy for esophageal or junctional cancer. N. Engl. J. Med. 366: 2074–2084.
73. Anonymous. 2015. NCCN clinical practice guidelines in oncology (NCCN guidelines)—esophageal and esophagogastric junction cancers. version 3. Accessed May 24, 2016. http://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf. 2015.
74. Mariette, C., G. Piessen & J.P. Triboulet. 2007. Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities. Lancet Oncol. 8: 545–553.
75. Stahl, M., C. Mariette, K. Haustermans, et al.; ESMO Guidelines Working Group. 2013. Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 24(Suppl. 6): vi51–vi56.
76. Burmeister, B.H., J.M. Thomas, E.A. Burmeister, et al. 2011. Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial. Eur. J. Cancer 47: 354–360.
77. Klevebro, F., G. Alexandersson von Dobeln, N. Wang, et al. 2016. A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction. Ann. Oncol. 27: 660–667.
78. Mukherjee, S., C.N. Hurt, S. Gwynne, et al. 2015. NEOSCOPE: a randomised phase II study of induction chemotherapy followed by either oxaliplatin/capecitabine or paclitaxel/carboplatin based chemoradiation as pre-operative regimen for resectable oesophageal adenocarcinoma. BMC Cancer 15: 48.
79. Leong, T., B.M. Smithers, M. Michael, et al. 2015. TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG). BMC Cancer 15: 532.
80. Cunningham, D., N. Starling, S. Rao, et al. 2008. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N. Engl. J. Med. 358: 36–46.
81. Hamilton, E., R.S. Vohra & E.A. Griffiths. 2014. What is the best neoadjuvant regimen prior to oesophagectomy: chemotherapy or chemoradiotherapy? Int. J. Surg. 12: 196–199.
82. Kumagai, K., I. Rouvelas, J.A. Tsai, et al. 2014. Meta-analysis of postoperative morbidity and perioperative mortality in patients receiving neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal and gastro-oesophageal junctional cancers. Br. J. Surg. 101: 321–338.
83. Kumagai, K., I. Rouvelas, J.A. Tsai, et al. 2015. Survival benefit and additional value of preoperative chemoradiotherapy in resectable gastric and gastro-oesophageal junction cancer: a direct and adjusted indirect comparison meta-analysis. Eur. J. Surg. Oncol. 41: 282–294.
84. Klevebro, F., G. Johnsen, E. Johnson, et al. 2015. Morbidity and mortality after surgery for cancer of the oesophagus and gastro-oesophageal junction: a randomized clinical trial of neoadjuvant chemotherapy vs. neoadjuvant chemoradiation. Eur. J. Surg. Oncol. 41: 920–926.
85. Markar, S.R., A. Karthikesalingam, S. Thrumurthy & D.E. Low. 2012. Volume–outcome relationship in surgery for esophageal malignancy: systematic review and meta-analysis 2000–2011. J. Gastrointest. Surg. 16: 1055–1063.
86. Boshier, P.R., O. Anderson & G.B. Hanna. 2011. Transthoracic versus transhiatal esophagectomy for the treatment of esophagogastric cancer: a meta-analysis. Ann. Surg. 254: 894–906.
87. Alldinger, I., L. Sisic, M. Hochreiter, et al. 2015. Outcome, complications, and mortality of an intrathoracic anastomosis in esophageal cancer in patients without a preoperative selection with a risk score. Langenbecks Arch. Surg. 400: 9–18.
88. Weijs, T.J., J.P. Ruurda, G.A. Nieuwenhuijzen, et al. 2013. Strategies to reduce pulmonary complications after esophagectomy. World J. Gastroenterol. 19: 6509–6514.
89. Wouters, M.W., G.A. Gooiker, J.W. van Sandick & R.A. Tollenaar. 2012. The volume–outcome relation in the surgical treatment of esophageal cancer: a systematic review and meta-analysis. Cancer 118: 1754–1763.
90. Brusselaers, N., F. Mattsson & J. Lagergren. 2014. Hospital and surgeon volume in relation to long-term survival after oesophagectomy: systematic review and meta-analysis. Gut 63: 1393–1400.
91. Dikken, J.L., A.E. Dassen, V.E. Lemmens, et al. 2012. Effect of hospital volume on postoperative mortality and survival after oesophageal and gastric cancer surgery in the Netherlands between 1989 and 2009. Eur. J. Cancer 48: 1004–1013.
92. Talsma, A.K., H.F. Lingsma, E.W. Steyerberg, et al. 2014. The 30-day versus in-hospital and 90-day mortality after esophagectomy as indicators for quality of care. Ann. Surg. 260: 267–273.
93. Vande Walle, C., W.P. Ceelen, T. Boterberg, et al. 2012. Anastomotic complications after Ivor Lewis esophagectomy in patients treated with neoadjuvant chemoradiation are related to radiation dose to the gastric fundus. Int. J. Radiat. Oncol. Biol. Phys. 82: e513–e519.
94. van Rossum, P.S., L. Haverkamp, H.M. Verkooijen, et al. 2015. Calcification of arteries supplying the gastric tube: a new risk factor for anastomotic leakage after esophageal surgery. Radiology 274: 124–132.
95. Zehetner, J., S.R. DeMeester, E.T. Alicuben, et al. 2015. Intraoperative assessment of perfusion of the gastric graft and correlation with anastomotic leaks after esophagectomy. Ann. Surg. 262: 74–78.
96. Aminian, A., N. Panahi, R. Mirsharifi, et al. 2011. Predictors and outcome of cervical anastomotic leakage after esophageal cancer surgery. J. Cancer Res. Ther. 7: 448–453.
97. Weijs, T.J., M.F. Seesing, P.S. van Rossum, et al. 2016. Internal and external validation of a multivariable model to define hospital-acquired pneumonia after esophagectomy. J. Gastrointest. Surg. 20: 680–687.
98. Reinersman, J.M., M.S. Allen, C. Deschamps, et al. 2015. External validation of the Ferguson pulmonary risk score for predicting major pulmonary complications after oesophagectomy. Eur. J. Cardiothorac. Surg. 49: 333–338.
99. Sakamoto, K., M. Oka, S. Yoshino, et al. 2014. Relationship between cytokine gene polymorphisms and risk of postoperative pneumonia with esophageal cancer. J. Gastrointest. Surg. 18: 1247–1253.
100. Dancer, R.C., D. Parekh, S. Lax, et al. 2015. Vitamin D deficiency contributes directly to the acute respiratory distress syndrome (ARDS). Thorax 70: 617–624.
101. D'Journo, X.B., P. Michelet, V. Marin, et al. 2010. An early inflammatory response to oesophagectomy predicts the occurrence of pulmonary complications. Eur. J. Cardiothorac. Surg. 37: 1144–1151.
102. Low, D.E., D. Alderson, I. Cecconello, et al. 2015. International consensus on standardization of data collection for complications associated with esophagectomy: Esophagectomy Complications Consensus Group (ECCG). Ann. Surg. 262: 286–294.